New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation

被引：6

作者：

Aguilar, Maria I. ^{[1
]}

Kuo, Ruth S. ^{[2
]}

Freeman, William D. ^{[3
,4
,5
]}

机构：

[1] Mayo Clin, Dept Neurol, Div Cerebrovasc Dis, Phoenix, AZ 85054 USA

[2] Scripps Mem Hosp, Dept Pharm, La Jolla, CA 92037 USA

[3] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA

[5] Mayo Clin, Dept Crit Care, Jacksonville, FL 32224 USA

来源：

NEUROLOGIC CLINICS | 2013年 / 31卷 / 03期

关键词：

Anticoagulation; Stroke; Atrial fibrillation; Reversal; Direct thrombin inhibitors; Factor Xa inhibitors; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; ORAL ANTICOAGULANTS; RISK STRATIFICATION; WARFARIN; REVERSAL; EFFICACY; SAFETY; CHA(2)DS(2)-VASC; THROMBIN; EDOXABAN; FOCUS;

D O I：

10.1016/j.ncl.2013.03.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.

引用

页码：659 / +

页数：18

共 32 条

[1]

[Anonymous], CIRCULATION

[2] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study [J].

Banerjee, Amitava ;

Lane, Deirdre A. ;

Torp-Pedersen, Christian ;

Lip, Gregory Y. H. .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) :584-589

[3] Edoxaban A New Oral Direct Factor Xa Inhibitor [J].

Camm, A. John ;

Bounameaux, Henri .

DRUGS, 2011, 71 (12) :1503-1526

[4]

Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]

[5] Apixaban in Patients with Atrial Fibrillation [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Joyner, Campbell ;

Diener, Hans-Christoph ;

Hart, Robert ;

Golitsyn, Sergey ;

Flaker, Greg ;

Avezum, Alvaro ;

Hohnloser, Stefan H. ;

Diaz, Rafael ;

Talajic, Mario ;

Zhu, Jun ;

Pais, Prem ;

Budaj, Andrzej ;

Parkhomenko, Alexander ;

Jansky, Petr ;

Commerford, Patrick ;

Tan, Ru San ;

Sim, Kui-Hian ;

Lewis, Basil S. ;

Van Mieghem, Walter ;

Lip, Gregory Y. H. ;

Kim, Jae Hyung ;

Lanas-Zanetti, Fernando ;

Gonzalez-Hermosillo, Antonio ;

Dans, Antonio L. ;

Munawar, Muhammad ;

O'Donnell, Martin ;

Lawrence, John ;

Lewis, Gayle ;

Afzal, Rizwan ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) :806-817

[6] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[7] Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents [J].

Crowther, M. A. ;

Warkentin, T. E. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 :107-110

[8] New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper [J].

De Caterina, Raffaele ;

Husted, Steen ;

Wallentin, Lars ;

Andreotti, Felicita ;

Arnesen, Harald ;

Bachmann, Fedor ;

Baigent, Colin ;

Huber, Kurt ;

Jespersen, Jorgen ;

Kristensen, Steen Dalby ;

Lip, Gregory Y. H. ;

Morais, Joao ;

Rasmussen, Lars Hvilsted ;

Siegbahn, Agneta ;

Verheugt, Freek W. A. ;

Weitz, Jeffrey I. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (16) :1413-1425

[9] Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial [J].

Easton, J. Donald ;

Lopes, Renato D. ;

Bahit, M. Cecilia ;

Wojdyla, Daniel M. ;

Granger, Christopher B. ;

Wallentin, Lars ;

Alings, Marco ;

Goto, Shinya ;

Lewis, Basil S. ;

Rosenqvist, Marten ;

Hanna, Michael ;

Mohan, Puneet ;

Alexander, John H. ;

Diener, Hans-Christoph .

LANCET NEUROLOGY, 2012, 11 (06) :503-511

[10] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

← 1 2 3 4 →